Q-omics provides the consensus-scored LRRTM1 profile across patient tissues and cancer cell-line models. LRRTM1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LRRTM1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, LRRTM1 RNA expression shows 13,602 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, BLCA, and TGCT as cancer lineages where LRRTM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRTM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRTM1 survival associations across molecular data types. LRRTM1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRTM1 RNA expression–survival associations across cancer types. High LRRTM1 expression shows unfavorable associations in MESO, KIRP, THCA and ACC, but favorable associations in LGG and OV. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for LRRTM1 RNA expression.
This table summarizes LRRTM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRRTM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRTM1 shows lower tumor expression in BLCA, HNSC, COAD, KIRC and STAD and higher tumor expression in KICH. The BLCA box plot shows higher LRRTM1 RNA expression in normal versus tumor tissue (log2 FC = −0.767, t-test p < 0.001).
This table shows molecular features associated with LRRTM1 in patient tissues and cancer cell lines. In patient samples, LRRTM1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRTM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
